Latest news from Iconovo

Biostock: Iconovo inleder 2024 med order från ledande läkemedelsbolag

Iconovo har erhållit en order från ett av världens tio största läkemedelsbolag. Dessutom stärker bolaget sin CDMO-affärsmodell genom att ingå ytterligare…

Iconovo signs additional contract with Kiox Pharma for the development of a new inhalable treatment for interstitial lung disease

Iconovo has entered into an agreement to continue the formulation development with Danish rare lung disease company Kiox Pharma. This is a continuation…

Iconovo launches improved versions of nasal ICOone inhalers

Iconovo launches improved versions of nasal ICOone. Both inhalers are designed for high technical performance and to minimize the risk of user error.…

Meet us


BIO-Europe Spring

March 18-20, 2024



March 18-21, 2024

New York

World Vaccine Congress 

April 1-4, 2024

Washington DC


April 24-25, 2024


RDD, Respiratory Drug Delivery 2024

May 5-9, 2024

Tucson, Arizona

Bio International Convention

June 3-6, 2024

San Diego


Redeye Life Science Days 

November 28, Stockholm

We are a specialized CDMO that develops inhalation products in our patented, innovative inhalers, supporting customers in bringing their inhaled treatments to market.

Learn more


Four differentiated technical platforms

We develop inhaled medicines from your drug substance as your complete inhalation partner. We take you all the way through your pharmaceutical product development, from idea to finalized inhalation product. Our strength is the integrated development of inhaler and dry powder formulation. Four differentiated technical inhaler platforms can be optimized with your unique dry powder formulation, and we also assist with manufacturing of clinical trial material in early clinical trials and technical documentation for registrations.

Learn more


Engineering and pharmaceutical expertise

Iconovo has an integrated development process, with all competences and facilities inhouse. With a unique combination of engineering and pharmaceutical expertise, our capabilities include devices, formulation, pharmaceutical analysis, and advisory services.

Learn more

Stay up to date with Iconovo’s news and press releases